Skip to content

Debt-to-assets at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
0.0×
ALN
Alnylam PharmaceuticalsALNY
0.1×0.0×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
0.0×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
0.1×0.0×
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
0.4×0.0×

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Calculated from Assembly Biosciences’s reported figures.

Based on the most recent quarter.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's debt-to-assets?
Assembly Biosciences (ASMB) reported debt-to-assets of 0× in Q1 2026.
How has Assembly Biosciences's debt-to-assets changed year-over-year?
Assembly Biosciences's debt-to-assets decreased by 65.2% year-over-year, from 0× to 0×.
What is the long-term trend for Assembly Biosciences's debt-to-assets?
Over 5 years (2020 to 2025), Assembly Biosciences's debt-to-assets has grown at a -22.2% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.